EXPLOITING AND DEFINING THE IMMUNE REGULATORY ACTIVITIES OF BET BROMODOMAIN INHIBITORS
Grant number: 1123432 | Funding period: 2017 - 2018
Immune-based agents such as “checkpoint inhibitors” have the ability to re-awaken our own immune systems and activate previously dormant anti-tumor responses. We have discovered that small molecule inhibitors of gene regulatory proteins called bromodomain proteins act synergistically with checkpoint inhibitors in mouse cancer models. We will define the molecular and biological events underpinning this novel combination approach and assess the effects of the combination across different tumors.